NCT04659629View on ClinicalTrials.gov

NL-201 Monotherapy and in Combination With Pembrolizumab in Patients With Relapsed or Refractory Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

59

Participants

Timeline

Start Date

April 26, 2021

Primary Completion Date

December 15, 2022

Study Completion Date

August 15, 2024

Conditions
Solid TumorAdvanced Solid Tumor
Interventions
DRUG

NL-201

NL-201 is a de novo protein therapeutic.

DRUG

Pembrolizumab Injection [Keytruda]

A programmed death receptor-1 (PD-1)-blocking antibody

Trial Locations (8)

2065

Melanoma Institute Australia, Sydney

10021

Memorial Sloan Kettering Cancer Center, New York

77230

UT- MD Anderson, Houston

97213

Providence Cancer Center Oncology and Hematology Care Clinic, Portland

98109

Seattle Cancer Care Alliance, Seattle

Unknown

St Vincents Hospital, Sydney

Olivia Newton-John Cancer Wellness & Research Centre, Heidelberg

M5G1Z5

UHN - Princess Margaret Cancer Center, Toronto

Sponsors

Lead Sponsor

Neurogene Inc.
All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

Neurogene Inc.

INDUSTRY

NCT04659629 - NL-201 Monotherapy and in Combination With Pembrolizumab in Patients With Relapsed or Refractory Cancer | Biotech Hunter | Biotech Hunter